French pharma firm sets up Pierre Fabre Fund for Innovation
To invest in French and European innovators in oncology and dermatology
French pharmaceutical group Pierre Fabre has established an innovation fund to invest in collaborations with start-ups, research laboratories and biotech companies specialising in oncology or dermatology.
The Pierre Fabre Fund for Innovation will support R&D projects either within two years from reaching clinical development or in the early stage of clinical development.
The support will consist of a range of differing types of partnership: providing Pierre Fabre’s expertise over the full pharmaceutical value chain, co-funding research programmes, acquiring a minority shareholding or licensing agreements. The combination of several types of support is also possible.
Pierre Fabre’s support in the long term will be conditional on reaching key milestones in the innovation process, the firm said.
Open to all international partnership opportunities, the main aim of the Pierre Fabre Fund for Innovation is to assist French and European innovators.
Pierre Fabre can offer these innovators a range of skills, including pharmacology, new chemical entities, biotherapies, immunotherapy, translational medicine, preclinical and clinical development, the manufacture of clinical batches and market access, as well as market and regulatory strategy.
The Pierre Fabre Fund for Innovation will be led by a Steering Committee comprising Bertrand Parmentier, Group CEO, Frédéric Duchesne, Pharmaceuticals CEO, Luc Péligry, Group CFO, Frédéric Desdouits, Business Development Director and Laurent Audoly, Pharmaceuticals R&D Director. Audoly will lead the operational management of the programme.
For more information email: fund.for.innovation@pierre-fabre.com